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INTRODUCTION
The term "haemoglobin switching" describes the sequential, highly regulated pattern of expression of the α-and β-like globin genes during development. 1 In humans, the ε-globin gene is expressed during the first eight weeks of gestation, followed by high level expression of the duplicated γ-globin genes during the fetal period. The γ-globin genes are expressed at very low levels (<1%) in the adult stage when expression of the β-globin gene predominates. A secondary level of developmental regulation characterizes expression of the γ-globin genes. The duplicated γ-globin genes can be distinguished by an amino acid difference at aa136 where the 5' Gγ-globin gene contains glycine while the 3' Aγ-globin gene contains alanine ( Figure 1 ). During the fetal period the Gγ-and Aγ genes are expressed in a ratio of 7:3, but in adult life this ratio is 2:3. The baboon (P. anubis) is an important animal model for studies of fetal hemoglobin regulation because the structure and developmental regulation of the β-globin gene complex is nearly identical to man. 2, 3 In the baboon the duplicated γ-globin genes are designated Iγ and Vγ because their amino acid sequence differs by the presence of an Ile or Val at aa75. 4 The ratio of Iγ/Vγ-globin expression is >9:5 in early gestational age (50-60dpc) fetuses, 3:2 at birth and 1:2 in the adult. 4, 5 Therefore the developmental pattern of expression of the baboon Iγ-and Vγ-globin genes is very similar to the human Gγ-and Aγ-globin genes ( Figure 1 ).
In sickle cell disease (SCD) the substitution of glutamic acid for valine at the sixth amino acid of the β-globin protein leads to the formation of abnormal hemoglobin S (HbS). 6 Following deoxygenation in red blood cells (RBCs), HbS forms polymers causing the RBCs to become deformed and adherent leading to painful vaso-occlusive events and organ injury. In vitro studies have shown that both fetal hemoglobin (HbF) (α 2 γ 2 ) tetramers and (α 2 β S γ) tetramers inhibit HbS polymerization. 7 Because increased levels of HbF lessen the severity of symptoms and increase the life expectancy of patients with SCD, therapeutic approaches to increase HbF levels would be highly desirable. 8, 9 While many drugs increase HbF in cultured erythroid cells, only a few have been shown to increase HbF in vivo. Studies in simian primate animal models that exhibit conservation of developmental globin gene regulation 10 , such as baboons, are considered one of the best tests of the activity of HbF-inducing drugs for therapies in patients designed to alleviate the symptoms of SCD and β-thalassemia.
11
Early studies in anemic baboons showed that treatment with the DNA methyltransferase inhibitor 5-azacytidine increased HbF to levels predicted to be therapeutic in patients. 12 Later studies confirmed that 5-azacytidine and its closely related analog decitabine did indeed increase HbF to therapeutic levels in patients with SCD and β-thalassemia. [13] [14] [15] [16] [17] [18] Based on experiments conducted in baboons, a phase 1 trial is currently in progress to test the safety and HbF-inducing activity of oral administration of decitabine in combination with the cytidine deaminase inhibitor tetrahydrouridine in SCD patients. 19 Hydroxurea (HU), the first drug approved for the treatment of SCD, was initially shown to increase HbF levels in monkeys 20 and subsequent clinical trials also confirmed that HU increased HbF levels in patients with SCD. 21 Because a large percentage of patients do not respond to HU, developing new drugs that increase HbF levels remains a priority.
The TR2/TR4 heterodimer and Bcl11A have been identified as γ-globin gene repressors that act by recruiting co-repressor complexes that establish repressive epigenetic modifications at specific sites to inactivate gene expression. 22 Recognition of the role of Direct Repeat (DR) elements in the ε-and γ-globin gene promoters in repression of these respective genes led to the identification of the TR2 and TR4
nonsteroidal nuclear receptor proteins that specifically bind these elements and subsequently recruit a multi-protein co-repressor complex that includes DNA methyltransferase 1 (DNMT1), lysine specific demethylase 1 (LSD1), and histone deacetylases (HDACs) to repress gene expression.
23-25
Both DNMT1 and LSD1 have also been identified as components of co-repressor complexes also recruited by Bcl11a.
26,27
LSD1, the first histone demethylase identified, demethylates lysine 4 (H3K4) and lysine 9 (H3K9) residues of histone H3 and represses gene expression during hematopoietic differentiation [28] [29] [30] . Tranylcypromine (TCP), an LSD-1 inhibitor, induced HbF production in cultured human hematopoietic erythroid progenitors and transgenic mice containing the entire human β-globin gene complex in the context of a yeast artificial chromosome (β-YAC mice).
31
Two recent studies have shown that RN-1, a more potent and specific LSD-1 inhibitor than TCP, induced γ-globin expression in human and baboon erythroid progenitors and a sickle cell mouse model. 32, 33 In this study we have tested the effect of RN-1 in baboons and confirm that it is a highly potent in vivo inducer of HbF synthesis.
METHODS

Baboons
Baboons were housed at the University of Illinois at Chicago Biologic Resources Laboratory (UIC BRL) under conditions that meet the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) standards. Bone marrow aspirations were performed from the hips of animals under ketamine/xylazine anesthesia (10 mg/kg; 1 mg/kg). Prior to bone marrow sampling, Buprenex (0.01 mg/kg IM) was given and later in the afternoon a second dose of Buprenex (0.01 mg/kg IM) was administered to alleviate potential pain and suffering.
The effect of RN-1 was tested in both anemic and non-anemic baboons.
Anemia was induced by repeated phlebotomies during a two-week period prior to administration of drug to attain a hematocrit (HCT) of 20 and animals were maintained at this HCT during the course of the experiment by periodic phlebotomies. Baboons were subjected to ketamine/midazolam (10 mg/kg; 3-5 mg/kg) anesthesia to allow removal of sufficient volumes of blood (15% of body weight) to induce and maintain anemia. RN-1 was dissolved in phosphate-buffered saline and passed through a 0.45 micron filter prior to administration by subcutaneous injection. All procedures were approved by the Animal Care Committee of the University of Illinois at Chicago
F-cells and F-reticulocytes
Levels of F-cells and F-reticulocytes were analyzed by flow cytometry using a Cytomics FC500 (Beckman Coulter) after staining with thiazole orange and PEconjugated anti-HbF (BD Bioscience).
HbF and globin chain synthesis
HbF levels in peripheral blood were determined by alkali denaturation.
34
Measurement of globin chain synthesis in peripheral blood reticulocytes was performed by biosynthetic radiolabeling of globin chains in the presence of [ 
35
For non-anemic animals, a fraction enriched in reticulocytes was obtained by centrifugation of 7 ml whole blood on Percoll step gradients as previously described. 36 Globin chain separation was achieved by high-performance liquid chromatography (HPLC) as previously described (Supplemental Methods).
37
RNA analysis
Real time PCR assays were performed as previously described 38 to determine levels of globin transcripts (Supplemental Methods).
Bisulfite Sequence Analysis
For bisulfite sequence analysis, DNA was purified from washed cell pellets using QIAmp Blood DNA Minikits. Bisulfite modification was performed using Epitect
Bisulfite kits (Qiagen #59104) according to the instructions of the manufacturer.
Amplification of bisulfite modified DNA was performed as previously described (Supplemental Methods).
35
Chromatin Immunoprecipitation Analysis
Chromatin immunoprecipitation analysis was performed as previously described 39 with modifications (Supplemental Methods).
Statistics
Student's t-test was used for all the statistical analyses. Error bars represent standard deviation.
RESULTS
Effect of RN-1 in anemic baboons
A series of dose-response experiments were conducted in anemic baboons to Table   2 ). The highest dose of RN-1 (2.5 mg/kg) increased HbF from 5.8% on the first day of drug treatment to 27.3% 7d after the last injection (Exp 1, Supplemental Table 2 ; Figure   2 ). Peak γ-globin chain synthesis (0.78 γ/γ+β) was observed 3d following the last day of drug administration demonstrating a near-complete reversion to fetal-stage synthesis Table 2 ; Figure 4 ) and F retics from 33.9 to 97.5%
(Supplemental Table 2 ; Figure 4 ). Neutropenia was observed with an ANC nadir of 570/μL 10d after the last RN-1 dose (Supplemental Table 2 Table 2 ; Figure 4 ). The decrease in ANC (nadir=870/μL) was less severe than at the higher doses (Supplemental Table 2 ; Figure 5 ). No changes in total hemoglobin production (α/γ+β=1.06+0.02) were observed in these three animals treated with the highest doses of RN-1. In a fourth experiment PA8548 was re-treated with a reduced RN-1 dose (0.2 mg/kg/d). HbF increased from 3.7% on the first day of treatment to 20.5% 6 days post-treatment (Exp 4, Supplemental Table 2 ; Figure 2 ). F-cells increased from 36.9% to 54.8% and Freticulocytes from 36.9% to 89.2% (Supplemental Table 2 ; Figure 4 ). Peak γ-globin chain synthesis (γ/γ+β) was 0.52 (Supplemental Table 2 ). Neutropenia (ANC nadir=800/μL) was observed (Supplemental Table 2 ; Figure 5 ). Another animal (PA8001) was treated with a reduced RN-1 dose (0.125 mg/kg/d) for 5d. HbF increased from 1.7% pre-treatment to 4.8% post-treatment, F cells increased from 13.5 to 21.8%
and F-reticulocytes from 22.9 to 31.7% (Supplemental Table 2 ; Figure 4 ). Neutropenia was not observed in this animal (Supplemental Table 2 ; Figure 4 ).
These experiments defined a linear dose relationship between HbF, F cells, and In an effort to achieve significant increases in HbF in the absence of neutropenia, PA8549 was re-treated with a dose of 0.125 mg/kg for 10 days (Exp 6, Supplemental Table 2 ). The HbF increased from 3.6% on the first day of treatment to 16% 5 days after the last injection. F-cells increased from 17.6% to 42.7% and F-reticulocytes from 21% to 70%. Peak γ-globin chain synthesis (γ/γ+β) was 0. Table 2 ).
The effect of RN-1 on globin mRNAs was determined in pre-and post-treatment peripheral blood samples in three animals treated with different doses (Supplemental Table 3 ). RN-1 treatment increased the level of γ-globin mRNA nearly fivefold (p<0.05) in post-treatment samples (0.39+0.12 γ/ε+γ+β) compared to pre-treatment samples (0.08+0.01 γ/ε+γ+β) while levels of ε-globin mRNA remained low.
Effect of RN-1 on histone modifications
To investigate the mechanism of action of RN-1, chromatin immunoprecipitation (ChIP) assays were performed to determine the effect of the drug on histone acetylation and methylation associated with the ε-, γ-, and β-globin genes. Increased levels of pol II associated with the γ-globin promoter (4.7 fold; p<0.02) and γ-globin IVS II region (3.2 fold; p<0.05) were observed. Levels of H3K9Ac were also increased at the γ-globin promoter (6.2 fold; p<0.01) and γ-globin IVS II regions (4.2 fold; p<0.02). Histone H3K4Me2 levels were increased at the γ-globin IVS II (2.1 fold;
p<0.05) but not at the γ-globin promoter while H3K4Me3 levels were increased at both the γ-globin promoter (4.7 fold; p<0.02) and at the γ-globin IVS II region (4.6 fold; p<0.02). No significant differences in the levels of these modifications at the ε-and β-globin promoter and IVS regions were observed between pre-and post-treatment samples. Levels of Histone H3K9Me2 were increased at the β-globin promoter (2.8 fold; p<0.02) and IVS II region (5.3 fold; p<0.01) in post-treatment samples.
Effect of RN-1 on DNA methylation
Bisulfite sequence analysis of the baboon 5' γ-globin promoter region in DNA γ/γ+β) compared to pre-treatment samples (0.09+0.04 γ/γ+β; p<0.01; Figure 6B ).
Effect of RN-1 in Non-anemic Baboons
To investigate whether the effect of RN-1 on γ-globin expression required Table 4 ) while two other animals (PA8695 and P8698, Exp 13 and 14, Supplemental Table 4 ) were treated with 0.25mg/kg/d RN-1 for 6 weeks.
Increased F cells were observed in all animals and ranged from 5 to 8 fold (Supplemental Table 4 : Figure 8 ). HbF levels increased 3-4 fold in all animals (Supplemental Table 4 , Figure 8 ). Within the F cell populations of the three baboons the HbF levels rose >3 fold (Supplemental Figure 3) . Importantly, these increases in HbF levels and F cells were associated with minimal neutropenia that resolved quickly (Supplemental Table 4 ; Supplemental Figure 4 ). In all three non-anemic animals treated for either 10 or 6 weeks increases in monocytes and decreases in platelets were also observed (Supplemental Figure 4) . Treatment of these non-anemic animals was not associated with changes in MCV or MCHC (Supplemental Figure 5 ). of genes. 43 The lack of effect of RN-1 on ε-globin expression in the baboon contrasts with increases in Εy and βh1 observed in the SCD mouse model. It is possible that this difference is dose-related and that the ε-globin gene is less sensitive to de-repression by RN-1 because the ε-globin promoter contains two DR elements that bind DRED with higher affinity than the single DR1 element in the γ-globin promoter. [22] [23] [24] LSD1 demethylates other proteins including DNMT1. Demethylation of DNMT1
Discussion
by LSD1 increases DNMT1 stability while targeted deletion of LSD1 in results in loss of DNMT1 and DNA demethylation in ES cells. 44 In this regard, we observed small effects on γ-globin promoter DNA methylation in BM erythroid cells from RN-1-treated baboons that were significantly less than changes previously observed in decitabine-treated baboons. DNA methylation changes are therefore not likely to be the major mechanism responsible for increased HbF levels in RN-1 treated baboons, although these small changes in DNA methylation could have contributed, in part, to the magnitude of the HbF response.
Because RN-1 is not covalently incorporated into DNA, as is decitabine and 5-azacytidine, it is potentially a less genotoxic and safer drug. The clinical usefulness of RN-1 will likely depend on the design of a dose and schedule that limit its undesirable effects on other hematopoietic lineages. The anemic baboon has been traditionally used and was initially developed to model the anemia and reticulocytosis observed in SCD. 12 In this model, anemia produced by repeated phlebotomies results in a nearcomplete replacement of the erythrocyte population within a two week period, removal of all formed elements, and alterations in levels of multiple cytokines in addition to erythropoietin. 45 To complement studies in anemic baboons, experiments were also performed in non-anemic animals where baseline hematopoiesis was not perturbed.
The neutropenia observed in phlebotomized baboons was lessened in non-anemic animals where ANC>1500 were generally maintained. The greater decreases in ANC in anemic animals may due to depletion of neutrophils by repeated phlebotomies or the effect of these phlebotomies on growth factor levels. Decreased platelets and increased monocyte counts were observed in both the anemic and non-anemic animals and likely are due to effects of the drug on hematopoietic differentiation. In an LSD1 conditional knockdown mouse model expansion of granulocytic, erythroid, and megakaryocytic progenitors was observed while granulopoiesis, erythropoiesis, and platelet production was inhibited suggesting that the similar effects observed in RN-1-treated baboons are due to inhibition of LSD1 activity. 30 RN-1 has been reported to affect long term memory in mice and therefore this may be an additional possible adverse effect of the drug. 46 Our results show that the LSD1 inhibitor RN-1 induces high levels of HbF in baboons and are consistent with previous studies showing that LSD1 plays a critical role in γ-globin silencing as a component of the DRED complex 25, 31 . A possible role for perturbation of erythroid differentiation in the mechanism of HbF reactivation cannot be negated, however, and the in vivo mechanism of action will be investigated in future studies. 
Supplemental Methods
Globin Chain Synthesis
Peripheral blood (20 µL) from anemic animals was washed three times in PBS and incubated overnight at 37°C in 0.2 mL leucine-free α-minimum essential medium (MEM; Invitrogen, Carlsbad, CA, USA) containing 20% dialyzed fetal bovine serum, transferrin, ferric ammonium citrate, and 50 µCi/mL L- [4, H] leucine (Perkin Elmer).
For non-anemic animals, a fraction enriched in reticulocytes was obtained by centrifugation of 7 ml whole blood on Percoll step gradients as previously described.
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The reticulocyte rich fraction was centrifuged (500 g; 10 min) and washed three times with PBS. The reticulocyte-rich pellet radiolabeled with [ Results are expressed as γ/γ+β chain ratios.
RNA analysis
RNA was isolated using the RNeasy Minikit (Qiagen #74104) and treated with RNase-free DNase I (Ambion #AM1906) according to the manufacturer's instructions.
Purified RNA was used for the synthesis of cDNA using RevertAid First Strand CDNA Synthesis Kits (Thermo Scientific #K1622). Real time PCR analysis was conducted using custom designed primer-probe combinations were used for analysis of globin transcripts (Supplemental Table 1 ). Absolute numbers of globin transcripts were determined by extrapolation from standard curves prepared from the cloned amplicons.
38
Bisulfite Sequence Analysis
Amplification of bisulfite modified DNA was performed as previously described.
35 with using the BG2 5'-AATAACCTTATCCTCCTCTATAAAATAACC and BG5 5'-GGTTGGTTAGTTTTGTTTTGATTAATAG primers. 35 Amplicons from three separate PCR reactions were pooled to reduce PCR bias and the amplicons cloned using Topo TA cloning kits (Life Technologies #K4575-01SC). DNA was isolated from individual clones and sequence analysis performed at the University of Illinois DNA Sequence Laboratory.
Chromatin Immunoprecipitation Analysis
Chromatin immunoprecipitation analysis was performed as previously Anti-pol II (sc-899x) was obtained from Santa Cruz Biotech. Immunoprecipitation was performed overnight at 4 o C followed by incubation with RNase A followed by a second incubation with Proteinase K. DNA from the chromatin immunoprecipitates was purified using ChIP DNA and Concentrators (Zymo Research). Quantitative real-time PCR of triplicate samples was performed using primers specific for the necdin, ε-, γ-, and β-globin promoters and ε-, γ-, and β-globin IVSII regions (Supplemental Table 1) with SBYR Green reagent using a 7500 Real Time PCR instrument (Applied Biosystems). 5 Standard curves constructed for each primer set using dilutions of input DNA were used to determine the relative amount of specific sequences recovered in samples following immunoprecipitation. Results were expressed as the fraction of input. 
Supplemental
